$RPRX — BUY 📊

$RPRX — BUY 📊 Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. 🎯 Q2 2026 | Rev $1B | EPS $1.30 vs $1.18 🟢 💡 Consensus expects moderating royalty cash flows due to patent cliffs; our variant view is that the beat reflects stronger underlying product performance and a robust pipeline of new royalty acquisitions that will sustain mid-single-digit growth, supporting multiple expansion from depressed levels. 📉 Reward/Risk: 3.05:1 🏢 Business Quality: 7/10 - Diversified portfolio of biopharmaceutical royalties generates high-margin, low-capex cash flows, but remains exposed to product lifecycle risks and drug pricing regulation. 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/RPRX0622

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.